Study: Circadian’s anti-cancer therapy reduces tumour growth in animal models

[News]

Circadian Technologies Limited today released data demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth in a variety of different animal models (tumour xenografts) of human cancer.

More... (http://www.news-medical.net/news/20100416/Study-Circadiane28099s-anti-cancer-therapy-reduces-tumour-growth-in-animal-models.aspx)